

THE ROLE OF PROBIOTICS AS ADJUVANT THERAPY IN INFLAMMATORY CARDIOVASCULAR DISEASES

Valensa Yosephi^{*1}, Noer Halimatus Syakdiyah¹, Peter Yustian Atmaja², Gatot Soegiarto^{3,4}

¹Master of Immunology Study Program, Postgraduate School, Universitas Airlangga, Surabava, Indonesia

²Department of Neurosurgery, dr. Moewardi General Hospital, Surakarta, Indonesia ³Department of Immunology, Postgraduate School, Universitas Airlangga, Surabaya,

Indonesia

⁴Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – dr. Soetomo General Academic Hospital, Surabaya, Indonesia

*E-mail : valensa.yosephi-2022@pasca.unair.ac.id

Abstrak

Penyakit kardiovaskular adalah penyebab utama kematian di seluruh dunia. Probiotik adalah mikroorganisme hidup yang dapat memberikan manfaat kesehatan bagi inang bila diberikan dalam jumlah yang memadai. Efek anti-inflamasi dari probiotik pada awalnya dipelajari pada penyakit Crohn (CD) dan kolitis ulserativa (UC). Penelitian ini bertujuan untuk memberikan bukti dan penjelasan ilmiah mengenai efek pemberian probiotik sebagai terapi adjuvan untuk penyakit inflamasi pada sistem kardiovaskular. Penelitian ini menggunakan pendekatan deskriptif dengan menggunakan metode tinjauan literatur sistematis pada PubMed, Scopus, SAGE, dan Web of Science. Sebanyak 13 artikel diinklusikan dalam penelitian ini. Probiotik yang digunakan termasuk Bifidobacterium dalam satu uji klinis, Lactobacillus dalam delapan uji klinis, Enterococcus dalam satu uji klinis, kombinasi Bifidobacterium dan Lactobacillus dalam satu uji klinis, dan kombinasi Lactobacillus dan Propionibacterium dalam satu uji klinis.

Kata Kunci: Inflamasi, penyakit kardiovaskular, probiotik, terapi adjuvan.

Abstract

Cardiovascular diseases are the leading cause of death worldwide. Probiotics are live microorganisms that can provide health benefits to the host when administered in adequate amounts. The anti-inflammatory effects of probiotics were initially studied in Crohn's disease (CD) and ulcerative colitis (UC). This research aim to provide scientific evidence and explanation on the effects of probiotic administration as adjuvant therapy for inflammatory diseases in cardiovascular health. The study employed a descriptive approach using the systematic literature review method on PubMed, Scopus, SAGE, and Web of Science. A total of 13 articles were included in this study. The probiotics used included Bifidobacterium in one clinical trial, Lactobacillus in eight clinical trials, Enterococcus in one clinical trial, a combination of Bifidobacterium and Lactobacillus in one clinical trial, and a combination of Lactobacillus and Propionibacterium in one clinical trial.

Keywords: Adjuvant therapy, cardiovascular diseases, inflammation, probiotics.

1. INTRODUCTION

2021. the World Health In Organization (WHO) stated that there were over 17.9 million deaths annually due to cardiovascular diseases, with one-third occurring in developing countries. This makes cardiovascular diseases the leading cause of death worldwide (WHO, 2021).

Acute myocardial infarction (AMI) is a form of coronary heart disease that occurs abruptly when the heart experiences ischemia for more than 30-45 minutes, causing irreversible cell damage leading to necrosis or death of the myocardium or heart muscle (Waly, & Listiyanto, 2014). The pathophysiology of acute myocardial 152

© (2024) Sekolah Pascasarjana Universitas Airlangga, Indonesia

infarction involves chronic inflammation in the endothelium and disturbances in platelets resulting in thrombosis and hypertension, leading to inappropriate angiogenesis (Blann et al., 2022).

Probiotics are live microorganisms when administered in that. adequate amounts, can provide health benefits to the host (Hill et al., 2014). Probiotics commonly found in fermented products such as bread, kefir, cheese, various dairy products, and others generally fall under the category of generally recognized as safe (GRAS), indicating they are considered safe for consumption (Brandelli, 2021; Rigobelo, 2012). Probiotics can be formulated into products. including various foods. medicines. and dietary supplements (Rigobelo, 2012). Some known usage of probiotics include anti-pathogenic, antidiabetic, anti-obesity, anti-inflammatory, anti-cancer, anti-allergy, and angiogenic activities (George Kerry et al., 2018). The anti-inflammatory effects of probiotics were initially studied in Crohn's disease (CD) and ulcerative colitis (UC) (George Kerry et al., 2018). Research indicates that an imbalance (dysbiosis) in gut microbiota plays a significant pathophysiological role in the positive regulation of inflammatory bowel Supplementation disease (IBD). of probiotics, prebiotics, and synbiotics can alter these disruptions (Cammarota et al., 2016).

There is no detailed explanation yet regarding the mechanism of action of probiotics in reducing inflammation. However, some speculated mechanisms include increased production of short-chain fatty acids with anti-inflammatory properties butyrate), enhancement (such as of antimicrobial peptide synthesis affecting inflammatory resolution pathways in the mucosa, and improvements in the intestinal luminal environment, intestinal mucosal barrier, and regulation of the mucosal immune system. Probiotics can influence various cells involved in innate and acquired immunity, such as DC, monocytes, Natural macrophages, Killer (NK) cells. lymphocytes, and epithelial cells (Cristofori et al., 2021). To date, there have been no studies on adjuvant probiotic therapy for inflammatory heart disease, prompting researchers to conduct studies on this topic. The results of this research are expected to provide scientific evidence and serve as a reference for further studies on the effects of probiotic administration as adjunctive therapy for inflammatory diseases in cardiovascular health.

2. RESEARCH METHOD

The study employed a descriptive approach using the systematic literature review method or structured article review. This paper was written using the systematic literature review method to identify, assess, and summarize research findings in a structured and systematic manner.

2.1 Article Selection Method

The selection criteria, comprising inclusion and exclusion criteria for the search of literature on the benefits of adjuvant probiotic therapy on the kidneys and heart, are presented in Table 1.



a : . :	cardiovascular	
Criteria Population	InclusionAdults (≥ 18years old) withacuteorchronic kidneydisease	 Exclusion Children (<18 tahun) Patients with comorbidities
Interventio n	Probiotic	 Prebiotic Synbiotic Sterile preparations
Outcome	 Pro- inflammation cytokine Anti- inflammation cytokine Serum lipid profile 	
Study Design	 RCT Placebo- controlled trials In-human studies Full-text article 	 Meta- analysis Systematic review Pooled data analyses Observat ive study Animal or <i>in</i> <i>vitro</i> studies Non-fulltext or abstract articles
Publication Time Limit	-	-
Language Limitations	English	Non-English

Table 1. Selection criteria for searching literature on the benefits of adjuvant probiotic therapy in

2.2 Article Search Methods

This study employed a literature search strategy utilizing online platforms, including searches on PubMed, Scopus, SAGE, and Web of Science. The list of database sites and keyword combinations for searching literature on the benefits of adjuvant probiotic therapy in the cardiovascular system is outlined in Table 2.

© (2024) Sekolah Pascasarjana Universitas Airlangga, Indonesia

 Table 2. Database sites and keyword combinations for searching literature on the benefits of adjuvant probiotic therapy in cardiovascular health


Database	Keyword Combination
Pubmed	(Ischemic Heart Disease OR
	Myocardial Ischemias OR
	Coronary Artery Diseases OR
	Coronary Atherosclerosis OR
	Hypercholesterolemia OR
	High Cholesterol Levels OR
	Elevated Cholesterol) AND
	(Probiotic OR Probiotic*)
	AND (Randomized controlled
	trial OR Clinical Trial)
Web of	(Ischemic Heart Disease OR
Science,	Myocardial Ischemias OR
SAGE,	Coronary Artery Diseases OR
Scopus	Coronary Atherosclerosis OR
_	Hypercholesterolemia) AND
	(Probiotic) AND (controlled
	trial)


2.3 Analysis Studies

The collected research data will be extracted and summarized narratively based on groups of research outcomes. The author will summarize and compile a descriptive record of the research in a tabular format. The research description table will outline a summary of all studies, including the researchers, publication year, and a summary of research findings. The summarized results in table form will be thoroughly reviewed for research methodology, process, and findings articles. obtained from the full-text Following a detailed and comprehensive review, the author will proceed with analysis and drawing conclusions. The synthesis of research findings and discussion will be utilized to derive conclusions.

3. RESULTS AND DISCUSSION

Out of the 38 clinical trials identified, 23 full-text articles were considered after implementing exclusion criteria. A total of 13 articles were included in this study. The PRISMA diagram can be seen in Figure 1.





Based on the systematic review, various studies utilized single-strain probiotics, while others employed multistrain probiotics. Detailed data regarding the studies included in the research can be found in Table 3. The probiotics used included *Bifidobacterium* in one clinical trial,

 \odot

© (2024) Sekolah Pascasarjana Universitas Airlangga, Indonesia



Lactobacillus in eight clinical trials, Enterococcus one clinical trial, in а combination of *Bifidobacterium* and Lactobacillus in one clinical trial, and a combination of Lactobacillus and Propionibacterium in one clinical trial.

In a clinical trial involving healthy subjects who received probiotic supplements for 12 weeks, 33 patients were tested with Bifidobacterium longum BB536 and red yeast rice (RYR). There was a decrease in LDL-c levels observed. Furthermore, the plasma lathosterol circulation, which is a marker for cholesterol synthesis, significantly reduced (p = 0.0206). The study found that B. longum BB536 and red yeast rice influenced lathosterol biosynthesis (Ruscica et al., 2019).

Ten clinical trials were conducted on participants with hypercholesterolemia, showing quite varied results. Significant reductions in total cholesterol were observed in the clinical trials by (Guerrero-bonmatty et al., 2021), (Costabile et al., 2017), (Fuentes et al., 2013), (Hlivak et al., 2005), (Ataie-Jafari et al., 2009), and (Chiu et al., 2021). A significant decrease in LDL was reported in the clinical trials by (Guerrerobonmatty et al., 2021), (Costabile et al., 2017), (Fuentes et al., 2013), and (Chiu et al., 2021). Two different results were found by (St-Onge et al., 2002) and (Hatakka et al., 2008), where no changes were observed in total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides or after supplementation. However, both clinical trials had a shorter supplementation duration compared to other studies, which was 4 weeks.

The study conducted by (Costabile et al., 2017) aimed to assess the effect of probiotics on proinflammatory cytokine levels. However, no significant changes were observed in IL-6, TNF- α , CRP, and IL-10

after 12 weeks of Lactobacillus plantarum supplementation. The clinical trial by Cavallini et al. found no changes in CRP levels. A study conducted on patients with a history of myocardial infarction by Moludi et al. showed a significant decrease in LPS and TNF- α levels between the probiotic group and the placebo group after administering L. rhamnosus GG (LGG) supplementation at 1.6×10^9 CFU/day for 12 weeks. The intake of Lactobacillus rhamnosus GG (LGG) showed beneficial effects in reducing metabolic endotoxemia and inflammation. Another study with 44 participants diagnosed with myocardial infarction and undergoing PCI found an increase in total antioxidant capacity, a decrease in MDA, and hs-CRP in the probiotic group (Moludi et al., 2022).





Table 3. Descriptive table of the effects of probiotics on inflammatory diseases in cardiovascular health

Author	Study design	Population	Control & Intervention Arms	Outcomes	Adverse Effects
(Ruscica et al., 2019)	Randomized, double- blind, placebo- controlled, parallel- group trial (RCT) in Italy	33 participants, aged 18-70 years, healthy subjects, low risk of cardiovascular disease	33 participants were randomly divided into a control group (n=17) and an experimental group (n=16). Probiotics were administered in the form of Lactoflorene Colesterolo supplements (Bifidobacterium longum BB536, with RYR extract, niacin, and coenzyme Q10) at a dosage of 1 sachet per day for 12 weeks	Significant differences were observed $(p < 0.005) \rightarrow$ TC decreased, LDL-C decreased, non- HDL-C decreased, and apoB decreased. However, TG, HDL-C, apoAI, Lp(a), PCSK9 did not change.	No side effects were observed
(Moludi et al., 2022)	Double- blind, four- arm parallel randomized controlled trial in Iran	96 participants, aged 18-85 years, with an average age of 51.25 years, diagnosed with coronary artery disease (CAD)	The 96 participants were randomly divided into 4 groups: control (n=24), probiotic group (n=24), inulin group (n=24), and probiotic-inulin group (n=24). Probiotic L. rhamnosus GG (LGG) at a dosage of 1.6×109 CFU/d was administered for 12 weeks	Significant differences observed between the probiotic group and the placebo \rightarrow LPS decreased, TNF- α decreased	No side effects were observed
(Guerrero- bonmatty et al., 2021)	Randomized, double- blind, placebo- controlled, parallel- group trial (RCT) in Spain	39 participants, aged 18-79 years, with total cholesterol levels >=200 mg/dL, not consuming statins	39 participants were randomly divided into a control group (n=18) and an experimental group (n=21). Probiotics: 109 CFU of L. plantarum strains CECT7527 (KABP011 TM), CECT7528 (KABP012 TM), and CECT7529 (KABP013 TM) in a 1:1:1 ratio with RYR extract. Analysis at baseline, 6 weeks, and 12 weeks	Significant differences observed → TC decreased (p=0.023), LDL decreased (p=0.011)	No side effects were observed

JBP Vol.24, No.2, December 2024 – Yosephi et al..

0 0 0

Jurnal Biosains Pascasarjana Vol. 26 (2024) © (2024) Sekolah Pascasarjana Universitas Airlangga, Indonesia

	· · · · · · · · · · · · · · · · · · ·	Pascasarjana Universit			NT 1 00
(Costabile et al., 2017)	parallel, double blind, placebo controlled, randomized design in UK	hypercholesterolemia; Aged = 30–65 years; Average BMI = 26.43	randomly divided into a control group (n=23) and an experimental group (n=23). Probiotics: Lactobacillus plantarum ECGC 13110402 4 × 109	Significant decrease in TC, LDL-C, TAG. However, there were no significant changes in IL-6, TNF-α, CRP, and IL-10 after 12 weeks	No side effects were observed
(Cavallini et al., 2016)	Randomized placebo- controlled double-blind trial	49 male participants with mild hypercholesterolemia; Aged = 45–48 years		In the fermented soy-probiotic group, HDL levels were maintained. There were no changes in CRP levels	No side effects were observed
(Jones et al., 2013)	Double- blind, placebo- controlled, randomized, parallel-arm, multicenter in Czech Republic	139 participants with hypercholesterolemia	Subjects with healthy hypercholesterolemia (LDL-c > 3.4 mmol/L; TG < 4.0 mmol/L; BMI range	circulation of	No side effects were observed
(Fuentes et al., 2013)	Controlled, randomised, double-blind trial in Spain	60 participants, aged 18-65 years, with hypercholesterolemia	The 60 participants were randomly assigned into a control group (n=30) and an experimental group (n=30). One	Reduced levels of TC, LDL-c, and LDL-c oxidation in the probiotic group. Decreased risk of CVD	

JBP Vol.24, No.2, December 2024 – Yosephi et al..

		casarjana Vol. 26 (202 Pascasarjana Universii		ia	
© (2	024) Sekolun 1	uscusurjunu Oniversii	plantarum (CECT 7527, CECT 7528, and CECT 7529) for 12 weeks	ιu	
(Hlivak et al., 2005)	Controlled, randomised, double-blind trial, Country not reported	43 participants with hypercholesterolemia	The 43 participants were randomized into two groups. Probiotic group, $n = 20$ (17 females, 3 males; Mean age = 75.35 ± 1.49 years; Mean BMI = 29.40 ± 0.86 kg/m2); Placebo group, $n = 18$ (14 females, 4 males; Mean age = 78.05 ± 1.68 years; Mean BMI = 29.08 ± 1.14 kg/m2) Probiotic: Enterococcus faecium M-74 and selenium (Se) \rightarrow two × 109 CFU/day; 50 µg of Se for 60 weeks	cholesterol levels in the probiotic group.	No side effects were observed
(Ataie- Jafari et al., 2009)	Randomized and crossover trial in Iran	14 participants with serum total cholesterol levels of 5.17-7.76 mmol/l, aged 40-64 years, with an average age of 50.5 years	They were randomly allocated into 2 groups to receive 300g of regular yogurt or probiotic yogurt (fermented with a starter comprising <i>Lactobacillus</i> <i>acidophilus</i> and <i>Bifidobacterium</i> <i>lactis</i> in addition to bacteria found in regular yogurt) for 6 weeks, followed by a 4-week washout period \rightarrow crossover	Significantly reduced TC levels in the probiotic yogurt group. Levels of LDL-C, HDL- C, LDL- C/HDL-C, and TAG showed no significant differences	No side effects were observed
(Chiu et al., 2021)	Double- blind, placebo- controlled, randomized clinical trial in Taiwan	40 participants with mild hypercholesterolemia, aged 18-60 years, with an average age of 42.5 years	The 40 participants were randomly divided into 2 groups, namely the control (n=20) and the probiotic group (n=20). Using a probiotic mixture in milk form (PMF) (bacterial strains) including L. acidophilus (La5), L. casei (TMC), and B. lactis (Bb12) at a concentration of 2 \times	Significantly increased (p <0.05) stool weight, bowel movements (reduction in defecation time) by enhancing gut microbiota (increase in beneficial bacterial species like Lactobacillus, Bifidobacterium	No side effects were observed

		casarjana Vol. 26 (202 Pascasarjana Universit		ia	
€ (2	024) Sekolun I	uscusurjunu Oniversi	106 CFU/g for 10 weeks	spp.), and LDL oxidation time. Total cholesterol (TC; 8.1%) and LDL- C (10.4%) levels significantly	
(Moludi et al., 2019)	Randomized, double- blind, and placebo- controlled clinical trial in Iran	44 participants diagnosed with myocardial infarction and underwent PCI	Out of the 44 participants, 42 were randomly divided into 2 groups, namely the control $(n=22)$ and the probiotic group $(n=22)$. Probiotic intervention: capsules containing 1.6×10 colony- forming units of Lactobacillus rhamnosus (active intervention group) or capsules containing maltodextrin (placebo control group) for 12 weeks	decreased There were significant differences observed in the increase in total antioxidant capacity, decrease in MDA, and hs- CRP levels in the probiotic group	One side effect occurred in the placebo group → experiencing symptoms of heart failure with reduced cardiac output
(St-Onge et al., 2002)	Randomized crossover trial, Country not reported	Thirteen male participants, aged 27 to 61 years (47 ± 9) years), with a BMI ranging from 26 to 38 kg/m2 (30.2 ± 4.4 kg/m2), and an average serum cholesterol of 6.54 ± 0.78 mmol/L were involved in the study	These 13 participants were divided into two groups: the first group consumed kefir supplements, while the second group consumed milk for 4 weeks. After a washout period of 4 weeks, they switched	Neither the kefir supplements nor the milk showed any reduction in total cholesterol, HDL cholesterol, LDL cholesterol, or triglyceride concentrations	At the onset of kefir supplementation, two subjects reported cramps and constipation. With milk consumption, one subject experienced bloating and increased bowel movements, while two subjects reported increased frequency of bowel movements or cramps
(Hatakka et al., 2008)	Double- blind, randomised, placebo- controlled, two-period crossover	38 participants with mild to moderate hypercholesterolemia, aged 24 to 55 years, with an average age of 42 years, were involved in the study	These 38 participants were divided into two groups. They were given treatment and a placebo for 4 weeks, after which the groups were	No changes in total cholesterol, HDL cholesterol, LDL cholesterol, or	No side effects were observed

JBP Vol.24, No.2, December 2024 – Yosephi et al..

Jurnal Biosains Pascasarjana Vo	<i>bl. 26 (2024)</i>	\odot \odot
© (2024) Sekolah Pascasarjana	Universitas Airlangga, Indonesia	
study with 4-	switched. The triglyceride	
week	treatment involved levels were	
treatment	probiotics: observed during	
periods in	Lactobacillus the	
Finland	rhamnosus strain consumption of	
	LC705 and probiotics	
	Propionibacterium compared to the	
	freudenreichii ssp placebo	
	shermanii strain JS in	
	capsules (2 x 1010	
	colony forming units	
	of each strain daily),	
	or two placebo	

capsules

cardiovascular diseases. In the intestines are a primary part of the body experiencing ischemia, where microvilli and colon villi become vulnerable to cellular hypoxia and anaerobic metabolism. All these factors eventually lead to an unstable gut microbiota composition (dysbiosis), mostly characterized by a decrease in Bifidobacteria and Bacteroides (Gram-positive bacteria) and an increase in Proteobacteria and (Gram-negative Firmicutes bacteria) (Alhajri et al., 2021).

Current research acknowledges the relationship between gut microbiota and the pathophysiology of heart and blood vessel diseases. Numerous studies have established that microbial metabolites, as well as components present in bacterial structures, can move from the gut to the general circulation, thus interacting and metabolically altering related tissue functions. Gut microbiota produce TMAO, SCFAs, and bile acids that have several metabolic effects in humans (Alhajri et al., 2021).

TMAO is a bacterial metabolite considered responsible for heart disease. TMAO can accumulate in the kidneys and heart, contributing to several biotic mechanisms, such as stimulating platelet accumulation, increasing foam cell synthesis, and activating inflammatory responses. Animal products like milk, red meat, and eggs, containing high levels of trimethylamine (TMA) groups, such as Lcarnitine and choline, are digested to produce TMAO (Guo et al., 2020). Studies have shown that increased TMAO can inhibit cholesterol transport and increase cholesterol accumulation in macrophages, thereby accelerating atherogenesis. Therefore, TMAO is pro-atherogenic, prothrombotic, and contributes to ischemic heart disease, being associated with a poor prognosis in heart failure patients (Alhajri et al., 2021).

0

Fermented dietary fiber produces short-chain fatty acids (SCFAs). The most common SCFAs include propionate (C3), acetate (C2), and butyrate (C4), encompassing 95% of the total SCFAs in the body. The concentration of these SCFAs in the gut ranges from 10 mM to 100 mM and functions within the digestive tract to activate ileum movement, mucus synthesis, and epithelial protection. Although most SCFAs are metabolized in the large intestine, a small portion is absorbed into the general circulation. Several experiments have revealed that SCFAs reaching the general cardiovascular circulation modulate functions (Chen et al., 2020).

Probiotics, such as Lactobacillus, Bifidobacterium, Lactococcus, and Streptococcus, can stimulate the growth and activity of specific gut microbiota, regulating

© (2024) Sekolah Pascasarjana Universitas Airlangga, Indonesia

immune responses and limiting inflammation levels, thus benefiting the host (Alhajri et al., 2021). Probiotics work differently bv directly or indirectly regulating the host. Firstly, they enhance the barrier function of the digestive tract through proteins from gap-junction intestinal epithelium and mucus secreted by goblet cells. Secondly, some probiotics can produce 'bacteriocins'. SCFAs. and other antimicrobial factors that inhibit pathogen growth. Thirdly, probiotics regulate the phenotype and activity of T cells, natural killer cells, and macrophages, reducing the release of proinflammatory factors by regulating the NF-κB pathway (Wang et al., 2020).

4. CONCLUSIONS

dysbiosis Microbial plays а significant role in the pathogenesis of various diseases. The gut microbiome and its metabolic products contribute to the pathophysiology and development of inflammatory diseases in the cardiovascular system. From the literature review findings, probiotics have the potential to serve as an adjuvant therapy inflammatory in cardiovascular diseases by repairing gastrointestinal cells, promoting **SCFA** formation, and modulating the body's immune system.

ACKNOWLEDGEMENT

The authors would like to express their gratitude to the reviewers for their time and expertise, Department of Immunology, Postgraduate School Universitas Airlangga, Lembaga Pengelola Dana Pendidikan (LPDP), The Ministry of Finance of the Republic of Indonesia for the support of the study.

BIBLIOGRAPHY

Alhajri, N., Khursheed, R., Ali, M. T., Abu Izneid, T., Al-Kabbani, O., Al-Haidar, M. B., Al-Hemeiri, F., Alhashmi, M., &

JBP Vol.24, No.2, December 2024 – Yosephi et al..



Pottoo, F. H. (2021). Cardiovascular Health and The Intestinal Microbial Ecosystem: The Impact of Cardiovascular Therapies on The Gut Microbiota. *Microorganisms*, 9(10), 2013.

https://doi.org/10.3390/microorganism s9102013

- Ataie-Jafari, A., Larijani, B., Alavi Majd, H., & Tahbaz, F. (2009). Cholesterol-Lowering Effect of Probiotic Yogurt in Comparison with Ordinary Yogurt in Mildly to Moderately Hypercholesterolemic Subjects. *Annals* of Nutrition and Metabolism, 54(1), 22– 27. https://doi.org/10.1159/000203284
- Blann, A. D., Brown, J. E., & Heitmar, R. (2022). Angiogenesis, Metabolism, Endothelial and Platelet Markers in Diabetes and Cardiovascular Disease. *British Journal of Biomedical Science*, 79.

https://doi.org/10.3389/BJBS.2022.103 13

- Cammarota, G., Pecere, S., Ianiro, G., Masucci, L., & Currò, D. (2016). of DNA-Based Principles Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. Digestive 34(3), 279-285. Diseases. https://doi.org/10.1159/000443362
- Cavallini, D. C. U., Manzoni, M. S. J., Bedani, R., Roselino, M. N., Celiberto, L. S., Vendramini, R. C., de Valdez, G.
 F., Abdalla, D. S. P., Pinto, R. A., Rosetto, D., Valentini, S. R., & Rossi, E. A. (2016). Probiotic soy product supplemented with isoflavones improves the lipid profile of moderately hypercholesterolemic men: A randomized controlled trial. *Nutrients*, 8(1).

https://doi.org/10.3390/nu8010052

Chen, X. F., Chen, X., & Tang, X. (2020). Short-chain fatty acid, acylation and cardiovascular diseases. *Clinical Science (London, England : 1979)*, *134*(6), 657–676. https://doi.org/10.1042/CS20200128 Chiu, H. F., Fang, C. Y., Shen, Y. C., Venkatakrishnan, K., & Wang, C. K. (2021). Efficacy of Probiotic Milk Formula on Blood Lipid and Intestinal Function in Mild Hypercholesterolemic Volunteers: A Placebo-control, Randomized Clinical Trial. *Probiotics* and Antimicrobial Proteins, 13(3), 624–632.

https://doi.org/10.1007/s12602-020-09728-6

- Costabile, A., Buttarazzi, I., Kolida, S., Quercia, S., Baldini, J., Swann, J. R., Brigidi, P., & Gibson, G. R. (2017). An in vivo assessment of the cholesterollowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. *PLOS ONE*, *12*(12), e0187964. https://doi.org/10.1371/journal.pone.01 87964
- Cristofori, F., Dargenio, V. N., Dargenio, C., Miniello, V. L., Barone, M., & Francavilla. R. (2021). Anti-Inflammatory and Immunomodulatory of Probiotics in Effects Gut Inflammation: A Door to the Body. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.57 8386
- Fuentes, M. C., Lajo, T., Carrión, J. M., & Cuñé, J. (2013). Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. *British Journal of Nutrition*, 109(10), 1866– 1872. https://doi.org/10.1017/S00071145120
- 0373X George Kerry, R., Patra, J. K., Gouda, S., Park, Y., Shin, H. S., & Das, G. (2018). Benefaction of probiotics for human health: A review. *Journal of Food and Drug Analysis*, 26(3), 927–939. https://doi.org/10.1016/J.JFDA.2018.0 1.002
- Guerrero-bonmatty, R., Gil-Fernández, G., Rodríguez-Velasco, F. J., & Espadalermazo, J. (2021). A combination of lactoplantibacillus plantarum strains cect7527, cect7528 and cect7529 plus

monacolin k reduces blood cholesterol: Results from a randomized, doubleblind, placebo-controlled study. *Nutrients*, 13(4).

https://doi.org/10.3390/nu13041206

- Guo, F., Zhou, J., Li, Z., Yu, Z., & Ouyang,
 D. (2020). The Association between
 Trimethylamine N-Oxide and Its
 Predecessors Choline, L-Carnitine, and
 Betaine with Coronary Artery Disease
 and Artery Stenosis. *Cardiology Research and Practice*, 2020.
 https://doi.org/10.1155/2020/5854919
- Hatakka, K., Mutanen, M., Holma, R., Saxelin, M., & Korpela, R. (2008). rhamnosus Lactobacillus LC705 Together with Propionibacterium freudenreichii shermanii ssp JS Administered in Capsules Is Ineffective in Lowering Serum Lipids. Journal of the American College of Nutrition, 27(4), 441-447. https://doi.org/10.1080/07315724.2008 .10719723
- Hlivak, P., Odraska, J., Ferencik, M., Ebringer, L., Jahnova, E., & Mikes, Z. (2005). One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. *Bratislavské Lekárske Listy*, 106(2), 67–72.
- Jin, M., Qian, Z., Yin, J., Xu, W., & Zhou, X. (2019). The role of intestinal microbiota in cardiovascular disease. *Journal of Cellular and Molecular Medicine*, 23(4), 2343. https://doi.org/10.1111/JCMM.14195
- Jones, M. L., Martoni, C. J., & Prakash, S. (2013). Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25hydroxyvitamin D: A post hoc analysis of a randomized controlled trial. *Journal of Clinical Endocrinology and Metabolism*, 98(7), 2944–2951. https://doi.org/10.1210/jc.2012-4262
- Moludi, J., Alizadeh, M., Mohammadzad, M. H. S., & Davari, M. (2019). The Effect of Probiotic Supplementation on Depressive Symptoms and Quality of Life in Patients after Myocardial

© (2024) Sekolah Pascasarjana Universitas Airlangga, Indonesia



Infarction: Results of a Preliminary Double-Blind Clinical Trial. *Psychosomatic Medicine*, 81(9), 770– 777.

https://doi.org/10.1097/PSY.00000000 00000749

- Moludi, J., Khedmatgozar, H., Nachvak, S. M., Abdollahzad, H., Moradinazar, M., & Sadeghpour tabaei, A. (2022). The co-administration effects of of probiotics and prebiotics on chronic inflammation. and depression symptoms in patients with coronary artery diseases: a randomized clinical trial. Nutritional Neuroscience, 25(8), 1659-1668. https://doi.org/10.1080/1028415X.202 1.1889451
- Ruscica, M., Pavanello, C., Gandini, S., Macchi, C., Botta, M., Dall'Orto, D., Del Puppo, M., Bertolotti, M., Bosisio, R., Mombelli, G., Sirtori, C. R., Calabresi, L., & Magni, P. (2019). Nutraceutical approach for the management of cardiovascular risk - A combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: Results from a randomized, double-blind, placebocontrolled study. Nutrition Journal, 18(1). https://doi.org/10.1186/s12937-019-0438-2
- St-Onge, M. P., Farnworth, E. R., Savard, T., Chabot, D., Mafu, A., & Jones, P. J. H. (2002). Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: A randomized controlled trial. *BMC Complementary and Alternative Medicine*, 2. https://doi.org/10.1186/1472-6882-2-1
- Waly, T. ., & Listiyanto, J. . (2014). Prevalensi Pasien Infark Miokard Akut Yang Menjadi Cardiac Arrest Di Icu/Hcu Rsup Dr. Kariadi Semarang. Jurnal Kedokteran Diponegoro, 3(1), 107458.
- Wang, Y., Liu, X., Shi, H., Yu, Y., Yu, Y., Li, M., & Chen, R. (2020). NLRP3 inflammasome, an immune-

inflammatory target in pathogenesis and treatment of cardiovascular diseases. *Clinical and Translational Medicine*, 10(1), 91–106. https://doi.org/10.1002/ctm2.13

WHO. (2021). Cardiovascular diseases. WHO Fact Sheet.